Key Takeaways
- Base business strong, Cenexi a drag: Ex-Cenexi EBITDA margin improved to 34% from 31%, while the Cenexi acquisition posted negative EBITDA due to one-time expenses and operational bottlenecks.
- U.S. volumes drive the story: Robust volume momentum for key products like levothyroxine and ketamine, with relatively stable pricing, propelled the quarter; management expects steady growth to continue in the near term.
- Cenexi thesis intact but delayed: Management reaffirmed the acquisition thesis but pushed its realization timeline to 12 to 15 months, citing capacity constraints and the slow pace of regulatory approvals for line changes.
- India de-emphasized: The domestic business declined 7% QoQ and is not a focus market, with management noting most products are under price control and the revenue contribution is small.
- What to watch next quarter: Whether Cenexi’s one-off costs truly clear and production volumes recover, the pace of new tech transfer revenue conversion, and any quantification of the lyophilization line shutdown impact.
Cenexi Integration: The Quarter’s Central Problem
- Operational bottlenecks: One facility is capacity-constrained with old lines that cannot deliver required volumes; shifting products to faster lines requires regulatory approvals, a process management acknowledges is slow.
- Profitability mechanics: Cenexi is a 75% margin asset, so any inventory reduction hits hard; lower production led to under-absorption of overheads, and a EUR 3 million EBITDA impact came from lower inventory versus the prior quarter.
- One-off costs: Employee and management restructuring charges, plus changes to pension provisions, added to the negative EBITDA print.
- Revenue bridge exists: A solid order book of new programs is in various stages of tech transfer and approval, with an anticipated EUR 3 crore to EUR 4 crore incremental annual revenue, but this will only materialize in FY26.
- Investment plan: The company will invest in new high-speed lines to replace old ones, automate processes, and ensure compliance; a new high-speed ampoule line plan is already progressing.
Srinivas Sadu: "These operational issues are causing delays in supplies and augmenting a backlog of orders."
Base Business Margins
- Ex-Cenexi margin walk: Gross margin improved due to product mix; EBITDA margin rose to 34% from 31% on rationalized power costs and human resources expenses.
- U.S. operating leverage: Selling more units leads to better absorption and margin improvement, a trend management has observed over the last few quarters.
- Raw material tailwind: For key products Ketorolac and Enoxaparin, raw material costs have fallen substantially; this passes through to end-market pricing, so margins are unaffected while the top line compresses.
- Temporary disruption: A two-week shutdown of one lyophilization line at Dundigal for a facility upgrade caused a supply disruption in March; management quantified the impact as not substantial.
U.S. Market: Volume Momentum, Stable Pricing
- Product-level strength: New products including levothyroxine, ropivacaine, ketamine, octreotide, and zinc sulfate saw robust volumes; previously launched products also experienced increased demand.
- Pricing environment: Management characterized the pricing environment as relatively stable.
- Oncology share: Launched cisplatin and carboplatin two quarters ago and have captured a 55% market share.
- Shortage list exposure: Some products are always on the FDA shortage list due to regulatory issues at competitor facilities; management indicated this dynamic is already reflected in current numbers.
- Customer concentration: The company supplies most top injectable front-end companies; clients who do not meet market share requirements get their allocation transferred to another customer.
Srinivas Sadu: "We're confident that we'll end the fiscal year '24 positively and continue to be excited about the opportunities ahead of us."
Ex-U.S. Markets: Rest of World Picks Up, India Steps Back
- RoW growth: A 7% QoQ increase was mainly attributable to Cenexi volumes; the company also won a tender in Saudi Arabia for 15 products.
- Primary markets steady: Performance in ex-U.S. primary markets remains consistent; the company is identifying products from its U.S. basket for Australia and Europe, though approval processes are longer.
- India deprioritized: Revenue declined 7% QoQ; management stated India is not a big focus market, most products fall under DPCO price control, and the revenue contribution relative to total turnover is small.
- Biologics slowdown: One plasma project is active and booking revenue, but funding for small buyers has slowed, causing a broader slowdown in the space.
Product Pipeline & Future Growth Levers
- Complex generics push: Growth is expected from RoW opportunities and U.S. complex generics; the company has entered contracts for cartridges and pen products.
- Filing cadence: Four more product filings are planned this year.
- Ex-Cenexi growth ambition: Management indicated mid-teens growth could be an internal target for the next 2 to 3 years, though this is qualified as aspirational and subject to how various options are evaluated.
- Regulatory footprint: The company held 1,659 product registrations worldwide as of December 31, 2023.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi acquisition thesis realization | Plan to realize the original acquisition thesis | Next 12 to 15 months |
| Cenexi EBITDA breakeven | Break even at EBITDA level | Next 12 to 15 months |
| Cenexi EBITDA margin target | Achieve 10% EBITDA margin | Midterm; FY25 described as reasonable |
| Cenexi incremental revenue from tech transfers | EUR 3 crore to EUR 4 crore incremental annual revenue | FY26 |
| Cenexi go-forward D&A from PPA | Approximately INR 9 crore to INR 14 crore per quarter | Ongoing from Q3 FY24 |
| Consolidated depreciation | Around INR 90 crores per quarter | Going forward |
| Ex-Cenexi growth ambition | Mid-teens growth target internally | Next 2 to 3 years |
| U.S. revenue trajectory | Steady growth to continue | At least in the near term |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹1,545.2 cr, +65% YoY and +13% QoQ |
| Base business revenue (ex-Cenexi) | +17% YoY and +9% QoQ |
| Gross margin | 61%, improved from 54% in Q3 FY23 |
| EBITDA | ₹355.7 cr, +23% YoY |
| EBITDA margin | 23%, compared to 31% in Q3 FY23 |
| Base business EBITDA margin (ex-Cenexi) | 34%, up from 31% in Q3 FY23 |
| Net profit | ₹191.9 cr, -17% YoY and -1% QoQ |
| PAT margin | 12% |
| R&D expenses | ₹53 cr, 5% of operating revenue (ex-Cenexi basis) |
| U.S. revenue | ~₹820 cr, +12% QoQ and +41% YoY |
| U.S. growth drivers | 8% from volumes, 3% from new launches, remainder from milestone and profit shares |
| Cenexi revenue | ₹443.9 cr, gross contribution of 75% |
| Cenexi EBITDA | Negative ₹17 cr, impacted by one-time expenses and lower productivity |
| Cash and equivalents (net) | ₹2,070.4 cr, gross cash of ₹2,479.5 cr less loans of ₹405.8 cr |
| Cash conversion cycle | 182 days for nine months ending Dec 2023, improved from 240 days in same period last year |
| ANDAs filed during quarter | 10 filed, 3 approved |
| Cumulative ANDAs | 346 filed, 279 approved, 67 pending as of Dec 31, 2023 |
| Capex (quarter) | ₹81 cr |
| Capex outlook (next financial year) | ~₹300 cr for Gland Pharma capacity expansion |